GTx, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'GTx, Inc. - Product Pipeline Review - 2016', provides an overview of the GTx, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by GTx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of GTx, Inc. - The report provides overview of GTx, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses GTx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features GTx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate GTx, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for GTx, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding GTx, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 GTx, Inc. Snapshot 5 GTx, Inc. Overview 5 Key Information 5 Key Facts 5 GTx, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 GTx, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 GTx, Inc. - Pipeline Products Glance 11 GTx, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 GTx, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 GTx, Inc. - Drug Profiles 13 enobosarm 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 GTx-758 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Beta-LGND2 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 GTx-026 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Gtx-027 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Gtx-186 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Gtx-230 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GTx-878 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Inhibit Tubulin for Cancer 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 GTx, Inc. - Pipeline Analysis 27 GTx, Inc. - Pipeline Products by Target 27 GTx, Inc. - Pipeline Products by Route of Administration 28 GTx, Inc. - Pipeline Products by Molecule Type 29 GTx, Inc. - Pipeline Products by Mechanism of Action 30 GTx, Inc. - Recent Pipeline Updates 31 GTx, Inc. - Dormant Projects 40 GTx, Inc. - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 toremifene citrate 41 GTx, Inc. - Company Statement 42 GTx, Inc. - Locations And Subsidiaries 45 Head Office 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
GTx, Inc., Key Information 5 GTx, Inc., Key Facts 5 GTx, Inc. - Pipeline by Indication, 2016 8 GTx, Inc. - Pipeline by Stage of Development, 2016 9 GTx, Inc. - Monotherapy Products in Pipeline, 2016 10 GTx, Inc. - Phase II, 2016 11 GTx, Inc. - Preclinical, 2016 12 GTx, Inc. - Pipeline by Target, 2016 27 GTx, Inc. - Pipeline by Route of Administration, 2016 28 GTx, Inc. - Pipeline by Molecule Type, 2016 29 GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30 GTx, Inc. - Recent Pipeline Updates, 2016 31 GTx, Inc. - Dormant Developmental Projects,2016 40 GTx, Inc. - Discontinued Pipeline Products, 2016 41
List of Figures
GTx, Inc. - Pipeline by Top 10 Indication, 2016 7 GTx, Inc. - Pipeline by Stage of Development, 2016 9 GTx, Inc. - Monotherapy Products in Pipeline, 2016 10 GTx, Inc. - Pipeline by Target, 2016 27 GTx, Inc. - Pipeline by Route of Administration, 2016 28 GTx, Inc. - Pipeline by Molecule Type, 2016 29 GTx, Inc. - Pipeline Products by Mechanism of Action, 2016 30
Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expeRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.